Skip to main content

Advertisement

Table 2 Univariate survival analysis

From: Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy

Variable HR 95% CI P value
Gender 0.75 0.38-1.32 0.24
Age 1.12 1.02-1.14 < 0.001
Performance status 0.98 0.92-1.02 < 0.001
Extent of surgery 0.14 0.10-0.28 < 0.001
MGMT methylation 1.25 1.12-1.32 0.006
TMZ therapy 0.24 0.12-0.41 < 0.001
SLC22A18 promoter methylation 0.64 0.32-1.15 0.13
SLC22A18 protein expression 2.14 1.24-3.72 0.01